Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program
EuroIntervention · 2026-05 · 22 (10) · 585-593
DOI: 10.4244/eij-d-26-00161 ↗Kurz gefasst
Fachartikel in der Zeitschrift EuroIntervention, 2026-05. Verfasst von David E Kandzari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Piedmont Heart Institute, Atlanta, GA, USA. Hauptthemen laut MEDLINE: Hypertension, Catheter Ablation, Kidney, Sympathectomy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Catheter-based renal denervation (RDN) is a guideline-recommended therapy for uncontrolled hypertension. Late-term follow-up among RDN trials is essential to characterise the durability of its efficacy, and further study is needed to ascertain the proportion of patients experiencing a clinical benefit. AIMS: We aimed to evaluate 36-month blood pressure (BP) changes after radiofrequency (RF)-RDN across four clinical studies from the SPYRAL programme and to determine the proportion of patients who experienced a clinical benefit. METHODS: Data were pooled from the Global SYMPLICITY Registry DEFINE, SPYRAL First-In-Human, and SPYRAL HTN-OFF MED and -ON MED trials. All patients were treated with RF-RDN (Symplicity Spyral). Medications, BP changes, and adverse events were evaluated through 36 months. RESULTS: A total of 2,137 patients treated with RF-RDN using the Spyral device were included in the analysis. Baseline office systolic (OS)BP was 163±23 mmHg, baseline 24-hour ambulatory systolic (AS)BP was 152±17 mmHg, and the baseline number of antihypertensive medications was 3.8±2.1. At 36 months, the number of medications was 3.5±1.9, and reductions in OSBP and ASBP were significant (-18.1±23.4 mmHg and -13.3±17.6 mmHg, respectively; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Piedmont Heart Institute, Atlanta, GA, USA.
- HOM-ICAREM (HOMburg Institute for CArdioREnalMetabolic Medicine), Medical Faculty, Campus Homburg, Saarland University, Homburg, Germany.
- University Hospital Erlangen, Erlangen, Germany.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Dobney Hypertension Centre, University of Western Australia - Royal Perth Hospital Research Foundation, Perth, Australia.
- Department of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Zitieren
APA
Kandzari, D. E., Böhm, M., Schmieder, R. E., Townsend, R. R., Schlaich, M. P., Kario, K., Whitbourn, R., Gilbertson, M., & Mahfoud, F. (2026). Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program. EuroIntervention, 22(10), 585-593. https://doi.org/10.4244/eij-d-26-00161
Vancouver
Kandzari DE, Böhm M, Schmieder RE, Townsend RR, Schlaich MP, Kario K, et al. Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program. EuroIntervention. 2026;22(10):585-593. doi:10.4244/eij-d-26-00161
BibTeX
@article{Kandzari2026,
author = {Kandzari, David E and Böhm, Michael and Schmieder, Roland E and Townsend, Raymond R and Schlaich, Markus P and Kario, Kazuomi and Whitbourn, Robert and Gilbertson, Miranda and Mahfoud, Felix},
title = {Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program},
journal = {EuroIntervention},
year = {2026},
volume = {22},
number = {10},
pages = {585--593},
doi = {10.4244/eij-d-26-00161}
}
EUVIMED